Merck Announces Phase III Trial Initiations for Four Investigational Candidates from its Promising Hematology and Oncology Pipeline

Merck announced the initiation of pivotal Phase III trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.